A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well

NCT05764122 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Ischemic Stroke

Interventions

DRUG: BIIB131
DRUG: Placebo

Sponsor

Biogen